id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-265170-yv04ijsm	Ceccarelli, Giancarlo	Probiotics and COVID-19	2020-07-13		.txt	text/plain	1124	69	36	SARS-CoV-2 has been postulated to affect gut inflammation both directly and indirectly, infecting intestinal epithelial cells through the angiotensin-converting enzyme 2 (ACE2) receptor and transmembrane protease serine 2, and inducing proinflammatory chemokine and cytokine release. 7 Given this evidence, bacteriotherapy could represent a complementary resource for the prevention and restoration of SARS-CoV-2 intestinal mucosa damage through the modulation of gut microbiota and decreasing related inflammation. In other infections, such as HIV, in which intestinal inflammation and related microbiota impairment can affect gut epithelial barrier function, bacteriotherapy (through microbiota surface compounds and metabolites) to exist between different probiotic bacterial species and strains. 8, 9 We believe that studies of bacteriotherapy in SARS-CoV-2 are needed to evaluate the potential effects on intestinal mucosal inflammation and microbiome homoeostasis. In the absence of a vaccine or effective therapy for COVID-19, we agree that probiotics represent a complementary approach for the prevention and restoration of SARS-CoV-2-induced mucosal damage or inflammation through the modulation of gut microbiota.	./cache/cord-265170-yv04ijsm.txt	./txt/cord-265170-yv04ijsm.txt